Compugen Ltd.
72 Pinchas Rosen Street
Tel Aviv
69512
Tel: 972-3-765-8585
Fax: 972-3-765-8555
Website: http://www.cgen.com/
Email: info@cgen.com
437 articles about Compugen Ltd.
-
Compugen Ltd. to Review Third Quarter 2008 Results on Thursday, November 13, 2008
11/4/2008
-
Compugen Ltd. Announces New Discovery Platform to Identify Viral Peptides for Use as Human Anti Inflammatory Drugs
10/23/2008
-
Compugen Ltd. Discovers Peptide Drug Candidate for Treatment of Solid Tumor Cancers and Announces Positive In Vivo Results
9/16/2008
-
Compugen Ltd. Retains Porter Novelli Life Sciences for U.S. Corporate Communications Initiative
9/9/2008
-
Compugen Ltd. Reports Second Quarter 2008 Results
7/29/2008
-
Compugen Ltd. to Review Second Quarter 2008 Results on Tuesday, July 29, 2008
7/22/2008
-
Compugen Ltd. Planning Proof of Concept Human Trial for Breast Cancer Drug Candidate in 2009
7/16/2008
-
Compugen Ltd. Announces Positive In-Vivo Results for Therapeutic Peptide Candidate for Immune Related Diseases
7/9/2008
-
Compugen Ltd. Announces Discovery of Biomarkers for Early Pre-Clinical Detection of Drug-Induced Kidney Toxicity
6/26/2008
-
Compugen Ltd. Announces Discovery of Novel Drug Targets for Cancer Antibody Therapeutics
6/11/2008
-
Compugen Ltd. to Highlight Company’s Therapeutic Discovery Platforms at BioMed Israel 2008
5/27/2008
-
Compugen Ltd. Presents Experimental Results for Three G-Protein Coupled Receptor (GPCR) Ligands
5/20/2008
-
Compugen Ltd. Reports First Quarter 2008 Results
5/14/2008
-
Compugen Ltd. First Quarter 2008 Conference Call to Be Held 10:00 AM EDT Wednesday, May 14, 2008
5/6/2008
-
Compugen Ltd. Announces Discovery of Blood Based Biomarker for Diagnosis of Lung Cancer
4/29/2008
-
Compugen Ltd. Discloses Novel Troponin Variant for Identification of Cardiac Muscle Injury, Receipt of Patent for the Molecule and Collaboration with Biosite Incorporated
4/1/2008
-
Compugen Ltd. Announces New Drug Discovery Platform to Predict Peptides that Block Disease-Associated Conformations of Proteins
3/18/2008
-
Compugen Ltd. Announces In-Vivo Results for Two Novel Peptide Agonists of MAS GPCR for Potential Treatment of Cardiovascular Pathologies
2/12/2008
-
Compugen Ltd. Announces In-Vivo Results for Two Peptide Anti-Inflammatory and Cardio-Protective Drug Candidates
1/29/2008
-
Compugen Ltd. Announces GPCR Ligand Discovery and License Option Agreement With Merck & Co., Inc.
1/14/2008